Candesant Biomedical

Candesant Biomedical, Inc.

is a medical device company dedicated to developing innovative solutions for excessive sweating, specifically through its FDA-cleared product, the Brella® SweatControl Patch. This non-invasive treatment targets axillary hyperhidrosis, or excessive underarm sweating, providing an effective alternative to existing therapies. The Brella Patch is designed for a quick in-office procedure that requires no downtime, making it convenient for patients. The Brella Patch utilizes Targeted Alkali Thermolysis (TAT) technology, which delivers focused heat to inactivate sweat glands. The treatment is administered by trained clinicians and typically lasts up to nine minutes, resulting in significant sweat reduction for three to four months after a single application. Candesant Biomedical aims to improve the quality of life for adults suffering from excessive sweating, with plans to expand its technology to treat other areas of hyperhidrosis in the future.